14 May 2026
May BNF + BNFC Knowledge Updates
British National Formulary
This update contains 29 significant changes, 3 dose changes, 2 new monographs, 2 new preparations, and 1 deleted monograph.
Significant changes
Adrenaline/epinephrine: name change to adrenaline.
Albumin solution: name change to albumin.
Anti-D (Rh0) immunoglobulin: name change to anti-D immunoglobulins.
Antidiabetic drugs and drugs with neuromuscular blocking effects: pharmacodynamic effects drug groups deleted from Interactions.
Cannabis extract: name change to cannabidiol with dronabinol.
Ceftazidime with avibactam: new indication and dose for bacteraemia.
Ceftazidime with avibactam: update to indication for Gram-negative infections.
COVID-19 vaccines: updated guidance on the Spring 2026 immunisation campaign.
Cyclogest® pessaries [progesterone]: new indication and dose for prevention of preterm birth.
Diphtheria with tetanus and pertussis vaccine: name change to diphtheria, tetanus, and pertussis vaccine.
Diphtheria with tetanus and poliomyelitis vaccine: name change to diphtheria, tetanus, and poliomyelitis vaccine.
Diphtheria with tetanus, pertussis and poliomyelitis vaccine: name change to diphtheria, tetanus, pertussis, and poliomyelitis vaccine.
Diphtheria with tetanus, pertussis, poliomyelitis and haemophilus influenzae type b vaccine: name change to diphtheria, tetanus, pertussis, poliomyelitis, and haemophilus influenzae type b vaccine.
Dried prothrombin complex: name change to prothrombin complex.
Drugs with anticoagulant effects and drugs with antiplatelet effects: pharmacodynamic effects drug groups combined and renamed as drugs that cause bleeding; see Interactions.
Dutasteride: update to monitoring requirements and effect on laboratory tests.
Finasteride: new monitoring requirements and update to effect on laboratory tests.
Haemophilus influenzae type b with meningococcal group C vaccine: name change to haemophilus influenzae type b and meningococcal group C vaccine.
Influenza: updated guidance on management.
Measles, mumps and rubella vaccine: name change to measles, mumps, and rubella vaccine.
Meningococcal group B vaccine (rDNA, component, adsorbed): name change to meningococcal group B vaccine.
Meningococcal groups A with C and W135 and Y vaccine: name change to meningococcal groups A, C, W135, and Y vaccine.
Molnupiravir: update to indication for COVID-19.
Noradrenaline/norepinephrine: name change to noradrenaline.
Obinutuzumab: new indication and dose for lupus nephritis.
Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change to pneumococcal polysaccharide conjugate vaccine.
Respiratory syncytial virus (RSV) vaccine: name change to respiratory syncytial virus vaccine.
Zanamivir: deleted indication and dose for treatment of influenza [uncomplicated, resistant to other treatments, and inhaled formulation unsuitable].
Zanamivir: update to indications for prophylaxis and treatment of influenza.
Dose Changes
Baloxavir marboxil [update to age ranges and dosing for post-exposure prophylaxis of influenza and treatment of influenza].
Oseltamivir [update to indication for post-exposure prophylaxis of influenza, and renal dosing in adults].
Utrogestan® vaginal capsules (progesterone) [update to dosing for supplementation of luteal phase during assisted reproductive technology (ART) cycles].
New Monographs
Imvanex® [smallpox and mpox vaccines] for Pre-exposure immunisation against smallpox and mpox [in patients previously unvaccinated against smallpox]; Pre-exposure immunisation against smallpox and mpox [in patients previously vaccinated against smallpox] Post-exposure prophylaxis against smallpox and mpox.
Itovebi® [inavolisib] for Breast cancer.
New Preparations
Misabri® [pregabalin] for Peripheral and central neuropathic pain.
Prometrium® [progesterone] for Threatened miscarriage [with vaginal bleeding and previous miscarriage] (initiated by a specialist).
Deleted monographs
Sotrovimab
BNF for Children
This update contains 21 significant changes, 2 dose changes, 2 new monographs, and 1 deleted monograph.
Significant changes
Adrenaline/epinephrine: name change to adrenaline.
Albumin solution: name change to albumin.
Anti-D (Rh0) immunoglobulin: name change to anti-D immunoglobulins.
Antidiabetic drugs and drugs with neuromuscular blocking effects: pharmacodynamic effects drug groups deleted from Interactions.
COVID-19 vaccines: updated guidance on the Spring 2026 immunisation campaign.
Diphtheria with tetanus and pertussis vaccine: name change to diphtheria, tetanus, and pertussis vaccine.
Diphtheria with tetanus and poliomyelitis vaccine: name change to diphtheria, tetanus, and poliomyelitis vaccine.
Diphtheria with tetanus, pertussis and poliomyelitis vaccine: name change to diphtheria, tetanus, pertussis, and poliomyelitis vaccine.
Diphtheria with tetanus, pertussis, poliomyelitis and haemophilus influenzae type b vaccine: name change to diphtheria, tetanus, pertussis, poliomyelitis, and haemophilus influenzae type b vaccine.
Dried prothrombin complex: name change to prothrombin complex.
Drugs with anticoagulant effects and drugs with antiplatelet effects: pharmacodynamic effects drug groups combined and renamed as drugs that cause bleeding; see Interactions.
Haemophilus influenzae type b with meningococcal group C vaccine: name change to haemophilus influenzae type b and meningococcal group C vaccine.
Influenza: updated guidance on management.
Measles, mumps and rubella vaccine: name change to measles, mumps, and rubella vaccine.
Meningococcal group B vaccine (rDNA, component, adsorbed): name change to meningococcal group B vaccine.
Meningococcal groups A with C and W135 and Y vaccine: name change to meningococcal groups A, C, W135, and Y vaccine.
Noradrenaline/norepinephrine: name change to noradrenaline.
Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change to pneumococcal polysaccharide conjugate vaccine.
Respiratory syncytial virus (RSV) vaccine: name change to respiratory syncytial virus vaccine.
Zanamivir: deleted indication and dose for treatment of influenza [uncomplicated, resistant to other treatments, and inhaled formulation unsuitable].
Zanamivir: update to indications for prophylaxis and treatment of influenza.
Dose Changes
Baloxavir marboxil [update to age ranges and dosing for post-exposure prophylaxis of influenza and treatment of influenza].
Oseltamivir [update to indication for post-exposure prophylaxis of influenza, and update to dosing for neonates in post-exposure prophylaxis of influenza].
New Monographs
Imvanex® [smallpox and mpox vaccines] for Pre-exposure immunisation against smallpox and mpox [in patients previously unvaccinated against smallpox]; Pre-exposure immunisation against smallpox and mpox [in patients previously vaccinated against smallpox] Post-exposure prophylaxis against smallpox and mpox.
Zavicefta® [ceftazidime with avibactam] for Complicated intra-abdominal infection, Complicated urinary tract infection [including pyelonephritis]; Hospital-acquired pneumonia [including ventilator-associated pneumonia]; Aerobic Gram-negative infections [in patients with limited treatment options] (administered on expert advice).
Deleted monographs
Sotrovimab
